Rhythm Pharma Reports Robust Long-Term Weight Loss with Setmelanotide in Hypothalamic Obesity, New Bivamelagon Data at ENDO 2026
Summary
Rhythm Pharmaceuticals announced strong new clinical data for its MC4R agonists, setmelanotide and bivamelagon, at ENDO 2026. Setmelanotide demonstrated a mean 18.9% BMI reduction over 2.5 years in acquired hypothalamic obesity (HO), reinforcing its long-term efficacy. New data for oral bivamelagon showed progressive BMI and hunger reductions in HO patients over one year. Additionally, real-world data for setmelanotide in Bardet-Biedl Syndrome (BBS) indicated improved weight outcomes. This positive data builds on the recent FDA approval and marketing authorization for IMCIVREE (setmelanotide) in acquired HO, and strong Q1 revenue.
At the time of this announcement, RYTM was trading at $89.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $60.70 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.